Armistice Capital LLC Buys 1,900,000 Shares of Autolus Therapeutics PLC Sponsored ADR $AUTL

Armistice Capital LLC boosted its position in shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) by 12.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 17,500,000 shares of the company’s stock after acquiring an additional 1,900,000 shares during the period. Armistice Capital LLC owned 0.07% of Autolus Therapeutics worth $34,825,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the company. R Squared Ltd boosted its position in shares of Autolus Therapeutics by 40.1% in the third quarter. R Squared Ltd now owns 30,476 shares of the company’s stock worth $50,000 after purchasing an additional 8,730 shares during the period. The Manufacturers Life Insurance Company raised its position in shares of Autolus Therapeutics by 41.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,419 shares of the company’s stock valued at $88,000 after purchasing an additional 11,289 shares during the period. Invesco Ltd. lifted its stake in shares of Autolus Therapeutics by 53.3% during the 1st quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock valued at $51,000 after buying an additional 11,381 shares in the last quarter. Marex Group plc bought a new position in Autolus Therapeutics in the 2nd quarter worth $28,000. Finally, Independent Advisor Alliance bought a new position in Autolus Therapeutics in the 4th quarter worth $28,000. Hedge funds and other institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Price Performance

Shares of AUTL opened at $1.53 on Thursday. The stock has a market capitalization of $407.22 million, a price-to-earnings ratio of -1.40 and a beta of 2.02. Autolus Therapeutics PLC Sponsored ADR has a 1 year low of $1.18 and a 1 year high of $2.70. The business’s 50 day simple moving average is $1.58 and its 200-day simple moving average is $1.56.

Autolus Therapeutics (NASDAQ:AUTL) last posted its earnings results on Friday, May 15th. The company reported ($0.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.02. Autolus Therapeutics had a negative net margin of 311.98% and a negative return on equity of 128.59%. The firm had revenue of $26.22 million during the quarter, compared to analyst estimates of $26.27 million. On average, sell-side analysts expect that Autolus Therapeutics PLC Sponsored ADR will post -0.96 earnings per share for the current year.

Analysts Set New Price Targets

AUTL has been the subject of a number of recent analyst reports. Jefferies Financial Group raised Autolus Therapeutics to a “strong-buy” rating in a research note on Monday, April 20th. Truist Financial raised shares of Autolus Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. Zacks Research raised shares of Autolus Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, March 13th. Needham & Company LLC reiterated a “buy” rating and issued a $10.00 price target on shares of Autolus Therapeutics in a research note on Thursday, April 9th. Finally, HC Wainwright increased their price objective on shares of Autolus Therapeutics from $9.00 to $10.00 and gave the company a “buy” rating in a report on Thursday, May 14th. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Autolus Therapeutics has an average rating of “Moderate Buy” and an average target price of $8.75.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.